Results 41 to 50 of about 180 (117)

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis

Neurology and Therapy, 2023
Cladribine tablets (CladT) is a highly active oral disease-modifying therapy (DMT) for the management of relapsing multiple sclerosis (RMS). CladT acts as an immune reconstitution therapy, in that two short courses of treatment 1 year apart have been shown to suppress disease activity for a prolonged period in most patients, without need for continued ...
Clavelou, Pierre, Castelnovo, Giovanni, Pourcher, Valérie, de Sèze, Jérôme, Vermersch, Patrick, Ben-Amor, Ali-Frederic, Savarin, Carine, Defer, Gilles   +7 more
openaire   +5 more sources

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2023
Background: Cladribine is an effective immunotherapy for people with multiple sclerosis (pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two treatment courses), disease activity re-emerges in others.
Kimberley Allen-Philbey, Stefania De Trane, Amy MacDougall, Ashok Adams, Lucia Bianchi, Thomas Campion, Gavin Giovannoni, Sharmilee Gnanapavan, David W. Holden, Monica Marta, Joela Mathews, Benjamin P. Turner, David Baker, Klaus Schmierer   +13 more
doaj   +1 more source

Clinical Trials With Pragmatic Elements: A Review of Use Cases and Real‐World Data Utilization

Clinical Pharmacology &Therapeutics, Volume 118, Issue 6, Page 1350-1365, December 2025.
Clinical trials with pragmatic elements can capture diverse patient populations, enable efficient follow‐up, and reflect routine clinical practices; yet there is limited understanding of their design features, characteristics, and use of real‐world data (RWD). Based on a targeted search of PubMed/EMBASE (Jan‐2016 to Jul‐2024), a review was conducted to
Le Su, Lei Chen, Seema Betigeri, Nancy Dreyer, Helga Gardarsdottir, Rachele Hendricks‐Sturrup, Mehmet Burcu   +6 more
wiley   +1 more source

Dysbiosis and Therapeutic Modulation of the Gut Microbiota in Multiple Sclerosis: A Narrative Review

Health Science Reports, Volume 8, Issue 12, December 2025.
ABSTRACT Background and Aims Multiple sclerosis (MS) is a persistent autoimmune disease that affects the central nervous system. The etiology of MS is complex, involving a variety of genetic and environmental factors. Mounting evidence suggests that dysbiosis significantly impacts the progression of MS mainly through its direct effects upon the immune ...
Mojtaba Memariani, Hamed Memariani
wiley   +1 more source

Insights into adherence to cladribine tablets in the real world in multiple countries: results from patient support programs

Therapeutic Advances in Neurological Disorders
Background: Patient support programs (PSP) help initiate and maintain disease-modifying treatment (DMT) for people with multiple sclerosis (PwMS). adveva ® (worldwide), Alcura Healthcare (Netherlands), and MS LifeLines ® (US) are nurse–pharmacy-led PSPs ...
Jiwon Oh, Mavis Ayer, Raed Alroughani, Samar Farouk, Mounir Khoury, Sabrina de Souza, Michela Bossolasco, Kate Morgan, Laura Negrotto, Tracey Quinn, Amir Boshra, Joseph Youssef, Murad Al-Naqshbandi, Kelly MacDonald, Meritxell Sabidó, Jeffrey M. Muir, Berenice Silva   +16 more
doaj   +1 more source

Metabolic Reprogramming of Cancer Cells and Therapeutics Targeting Cancer Metabolism

Cancer Medicine, Volume 14, Issue 18, September 2025.
ABSTRACT Background Cancer metabolism is a field focused on the unique alterations in metabolic pathways that occur in cancer cells, distinguishing them from the metabolic processes in normal cells. Methods An extensive review of the current literature on the metabolic adaptation of cancer cells was carried out in the current study. Results The rapidly
Jilsy M. J. Punnasseril, Abdul Auwal, Vinod Gopalan, Alfred King‐Yin Lam, Farhadul Islam   +4 more
wiley   +1 more source

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients

Therapeutic Advances in Neurological Disorders, 2021
Objective: To report on safety and effectiveness of subcutaneous cladribine (Litak ® ) in multiple sclerosis (MS) patients. Methods: Litak ® was offered to MS-patients irrespective of disease course.
Kimberley Allen-Philbey, Stefania De Trane, Zhifeng Mao, Cesar Álvarez-González, Joela Mathews, Amy MacDougall, Andrea Stennett, Xia Zhou, Ozlem Yildiz, Ashok Adams, Lucia Bianchi, Camilla Blain, Christine Chapman, Karen Chung, Cris S Constantinescu, Catherine Dalton, Rachel A Farrell, Leonora Fisniku, Helen Ford, Bruno Gran, Jeremy Hobart, Zhaleh Khaleeli, Miriam Mattoscio, Sue Pavitt, Owen Pearson, Luca Peruzzotti-Jametti, Antonio Scalfari, Basil Sharrack, Eli Silber, Emma C Tallantyre, Stewart Webb, Benjamin P Turner, Monica Marta, Sharmilee Gnanapavan, Gunnar Juliusson, Gavin Giovannoni, David Baker, Klaus Schmierer   +37 more
doaj   +1 more source

Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study

Frontiers in Neurology
Patient-reported outcomes (PROs) are essential for understanding the effects of MS and its treatments on patients’ lives; they play an important role in multiple sclerosis (MS) research and practice.
Giovanna Borriello, Giovanna Borriello, Clara Grazia Chisari, Clara Grazia Chisari, Davide Maimone, Massimiliano Mirabella, Massimiliano Mirabella, Damiano Paolicelli, Francesco Assogna, Sandro Caradonna, Francesco Patti, Francesco Patti   +11 more
doaj   +1 more source

Model‐informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets

Clinical and Translational Science, 2022
Cladribine tablets have been approved in many countries for the treatment of patients with various forms of relapsing multiple sclerosis (MS). Cladribine has a unique pharmacokinetic/pharmacodynamic (PK/PD) profile with a short elimination half‐life (~ 1 
Alain Munafo, Nadia Terranova, Dandan Li, Ping Liu, Karthik Venkatakrishnan   +4 more
doaj   +1 more source

Langerhans Cell Histiocytosis With MAP2K1E102_I103del Mutation Successfully Treated With Trametinib

eJHaem, Volume 6, Issue 3, June 2025.
ABSTRACT The discovery of the MAPK pathway mutations in lesions of patients with Langerhans cell histiocytosis (LCH) has made targeted therapy an important therapeutic approach for these patients. Theoretically, the RAF‐independent mutation MAP2K1E102_I103del is naturally resistant to allosteric MEK inhibitors.
Min Lang, Long Chang, Xin‐xin Cao
wiley   +1 more source